NCT06265363

Evaluation of the Frequency, Risk Factors, and Outcomes of ROP in Infants With a BW 1500 Grs or GA ≥33 Wks in Turkey.

Name: Clinical Trial NCT06265363
Creator: Baskent University Ankara Hospital
Keywords: Retinopathy of Prematurity, clinical trial, Turkey

Evaluation of the Frequency of Retinopathy of Prematurity, Influencing Risk Factors, and Treatment Outcomes in Premature Infants With a Birth Weight 1500 Grams or Gestational Age ≥33 Weeks in Turkey. (TR-BigROP)

Baskent University Ankara Hospital·ClinicalTrials.govRecruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Retinopathy of Prematurity
Study type: Observational

Sponsor & location

Primary sponsor: Baskent University Ankara Hospital
Location: Ankara, Turkey

Timeline & enrollment

Phase: N/A
Start date: Aug 01, 2023
End date: Nov 01, 2024
Enrollment: 1000 participants

Primary outcome

Incidence of ROP

Summary

The study includes preterm infants who are being screened for ROP between August 1,2023 and August 1, 2024 in 94 neonatal intensive care units (NICUs) in Turkey. Infants with birth weight (BW) of 1500 g or ≥ 33 weeks' gestation who are screened for retinopathy of prematurity are included. The incidence of any ROP, severe ROP and treatment modalities will be determined. The risk factors for ROP development will also be evaluated.

ICD-10 classifications

Retinopathy of prematurityOther proliferative retinopathyBackground retinopathy and retinal vascular changesDiabetic retinopathyRetinal disorder, unspecified

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06265363
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06265363 through Pure Global AI's free database. This phase not specified trial is sponsored by Baskent University Ankara Hospital and is currently Recruiting. The study focuses on Retinopathy of Prematurity. Target enrollment is 1000 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.